- Home
- PHAR vs OLMA Comparison
PHAR vs OLMA Comparison
Compare PHAR & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- OLMA
- Stock Information
- Founded
- PHAR 1988
- OLMA 2006
- Country
- PHAR Netherlands
- OLMA United States
- Employees
- PHAR N/A
- OLMA N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- OLMA Health Care
- Exchange
- PHAR Nasdaq
- OLMA Nasdaq
- Market Cap
- PHAR 951.7M
- OLMA 378.9M
- IPO Year
- PHAR N/A
- OLMA 2020
- Fundamental
- Price
- PHAR $14.60
- OLMA $7.75
- Analyst Decision
- PHAR Strong Buy
- OLMA Strong Buy
- Analyst Count
- PHAR 3
- OLMA 5
- Target Price
- PHAR $30.00
- OLMA $24.00
- AVG Volume (30 Days)
- PHAR 12.7K
- OLMA 1.1M
- Earning Date
- PHAR 10-23-2025
- OLMA 11-11-2025
- Dividend Yield
- PHAR N/A
- OLMA N/A
- EPS Growth
- PHAR N/A
- OLMA N/A
- EPS
- PHAR N/A
- OLMA N/A
- Revenue
- PHAR $339,836,000.00
- OLMA N/A
- Revenue This Year
- PHAR $16.63
- OLMA N/A
- Revenue Next Year
- PHAR $6.77
- OLMA N/A
- P/E Ratio
- PHAR N/A
- OLMA N/A
- Revenue Growth
- PHAR 22.44
- OLMA N/A
- 52 Week Low
- PHAR $7.31
- OLMA $2.86
- 52 Week High
- PHAR $17.08
- OLMA $13.93
- Technical
- Relative Strength Index (RSI)
- PHAR 56.71
- OLMA 64.67
- Support Level
- PHAR $13.63
- OLMA $7.49
- Resistance Level
- PHAR $15.27
- OLMA $8.40
- Average True Range (ATR)
- PHAR 0.96
- OLMA 0.67
- MACD
- PHAR -0.13
- OLMA 0.08
- Stochastic Oscillator
- PHAR 51.83
- OLMA 75.63
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.